

Japan's Chugai Pharma signs exclusive license agreement with GSK for anti-dengue virus antibody AID351

August 20, 2026 | News

To develop, manufacture, and commercialise a new antibody drug AID351, which is being developed for dengue fever



Japan-based Chugai Pharmaceutical has signed an exclusive license agreement with British pharma firm GlaxoSmithKline (GSK) for the anti-dengue virus antibody "AID351".

Under this agreement, GSK obtains an exclusive, worldwide license from Chugai to develop, manufacture, and if successful commercialize with respect to AID351, which is expected to be used to manage flavivirus infections, including dengue fever. GSK will be responsible for the clinical development, including Phase I clinical trials, and the manufacturing of the asset. Chugai is eligible to receive royalties based on future product sales by GSK, if successful, as well as a percentage of any sublicensing income received by GSK from third parties.

This agreement builds on a joint development initiative for an anti-dengue virus antibody aimed at overcoming dengue fever, which is classified by the World Health Organization (WHO) as one of the Neglected Tropical Diseases (NTDs).

The project has been advanced through collaboration between Chugai Pharmabody Research (CPR), the Chugai Pharmaceutical Group's research base in Singapore, and A*STAR Singapore Immunology Network (A*STAR SiGN), using an antibody derived from A*STAR SiGN and the National University of Singapore (NUS) as the lead. During this period, the project received grant funding twice from the Global Health Innovative Technology (GHIT) Fund.

Through this partnership, Chugai and GSK aim to further accelerate the development of an innovative new drug for dengue fever.